Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Imperial College London: Clinical Trials & FDA Approval Profile

Imperial College London (Global / Institutional) sponsors 44 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 19 active protocols (7 recruiting now), 14 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)11.4%
Median Closed Enrollment vs National (145 pts)35 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Imperial College London
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)44
Active Pipeline (Recruiting Now)19 (7)
Completed vs Stopped Early14 / 5 (11.4%)
Median Closed Actual Enrollment35 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Imperial College London
Hospital Research SiteLocationShared Protocols
Imperial College Healthcare NHS TrustLondon15
Nottingham University Hospitals NHS TrustNottingham, Nottinghamshire (county)4

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Imperial College London
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05085028A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With AdvancedPhase IIIRECRUITING
NCT04319367A Randomised Placebo Controlled Trial of ART Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies (bNAbs).Phase IIRECRUITING
NCT05889507Cooling in Mild EncephalopathyPhase IIIRECRUITING
NCT06230354Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With PolyangiitisPhase IIACTIVE NOT RECRUITING
NCT03775109IL-1 Signal Inhibition in Alcoholic HepatitisPhase IICOMPLETED

Explore interactive annual charts and M&A subsidiary rollups in the Imperial College London Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI